Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first ...

We recently published a list of the 11 Most Promising Long-Term Stocks According to Analysts. In this article, we are going ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative ...

Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 18 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent ...

Investors with significant funds have taken a bearish position in Sarepta Therapeutics (NASDAQ:SRPT), a development that retail traders should be aware of. This was brought to our attention today ...

Sarepta Therapeutics Background Information (This ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial data and insights ...

Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of limb-girdle muscular dystrophy (LGMD), a group of rare genetic disorders ...

There are 956 funds or institutions reporting positions in Sarepta Therapeutics ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

Shares of Sarepta Therapeutics declined after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). This hold has been ...

(RTTNews) - Sarepta Therapeutics (SRPT ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (BMV:SRPT) from Outperform to Sector Perform. There are 956 funds or institutions reporting ...